# Feasibility of Intensive Chemotherapy in Hereditary Spherocytosis

## TL;DR

A young man with hereditary spherocytosis successfully underwent intensive chemotherapy for lymphoma, showing that the condition need not prevent standard treatment.

## Contribution

Demonstrates that HS patients can tolerate aggressive chemotherapy with careful monitoring and support.

## Key findings

- The patient achieved complete remission after intensive chemotherapy for DLBCL.
- Close monitoring and timely transfusions prevented complications from chemotherapy stress.
- HS should not automatically exclude patients from curative lymphoma treatments.

## Abstract

Background: This study presents a young man with hereditary spherocytosis (HS) who underwent intensive chemotherapy for newly diagnosed diffuse large B-cell lymphoma (DLBCL) and achieved complete remission. This case challenges the idea of HS as a barrier to standard DLBCL treatment. Discussion: By meticulously monitoring blood counts and providing timely transfusions, the team successfully mitigated potential complications associated with chemotherapy-induced stress on red blood cells. Conclusions: This experience underscores the importance of a multidisciplinary approach and tailored treatment plans for patients with co-existing conditions, suggesting that HS should not automatically disqualify them from potentially curative therapies for aggressive lymphomas.